Glaxo Group Limited

Glaxo Wellcome Inc.

Martin Redpath Johnson

Michael D Dowle

Harry Finch

Lee Andrew Harrison

Paul Spencer Jones

Mika Lindvall

Simon John Fawcett MacDonald

Pritom Shah

Caroline Mary Cook

Christopher David Edlin

Diane Mary Coe

Julie Nicole Hamblin

Peter C North

Charlotte Jane Mitchell

Anthony William James Cooper

Alison Judith Redgrave

Graham George Adam Inglis

Robin Andrew Smith

Graham George Inglis

Siegfried B Christensen, Iv

Alexander W Oxford

Naimisha Trivedi

David George Allen

Lionel Trottet

John Edward Robinson

Amyn Pyarali Sayani

Simon John MacDonald

The invention provides 4-{[1-(aminocarbonyl)-4-piperidinyl]amino}-N-[(3,4-dimethylphenyl)methyl]-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide, which is the compound of formula (I): or a salt thereof.

Pyrazolo[3,4-b]pyridine compound, and its use as a PDE4 inhibitor

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or &#x2014;(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substituted Ccycloalkyl, optionally substituted mono-unsaturated-Ccycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which nand nindependently are 1 or 2; and Y is O, S, SO, or NR; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors

The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Et, n-Pr, i-Pr, Cfluoroalkyl, or &#x2014;CHCHOH; wherein Ris methyl or ethyl; Ris H, methyl or ethyl; Ris H, methyl or ethyl, Ris H, methyl or ethyl, and Ris H or methyl, These compounds are PDE4 inhibitors.

[object Object]

According to the invention are provided compounds of formula (I) (relative stereochemistry indicated) wherein R,, R,and R,are as defined in the specification. Compounds of formula (I) are useful inter alia in the treatment of inflammatory diseases of the respiratory tract.

Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

There are described according to the invention, processes for making compounds of formula (XXVIII),(relative stereochemistry indicated), wherein P,is as defined in the specification.

According to the invention there are provided Hexahydro-Pyrrolo&lsqb;3,4-b&rsqb;pyrrol-2-one compounds of formula (1), (relative stereochemistry indicated), wherein R,, R,and R,are as defined in the specification. Compounds of formula (1) are useful inter alia in the treatment or chronic bronchitis.

Pyrrolopyrrolone derivatives

Indolyl compounds and their use in treatment of cephalic pain

Compounds are disclosed of formula (I) ##STR1## wherein R.sub.1 represents a C.sub.1-6 alkyl group;

Indole derivatives

Growing community of inventors

Stevenage, United Kingdom

Martin Redpath Johnson